Piramal Pharma

226.72
+7.68
(3.51%)
Market Cap
29,039.20 Cr
EPS
0.14
PE Ratio
493.75
Dividend Yield
0.05 %
Industry
Healthcare
52 Week High
307.90
52 Week Low
118.25
PB Ratio
3.79
Debt to Equity
0.70
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from6 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy+100.00 %
+100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Piramal Critical Care's Neoatricon® Receives MHRA Approval in UK4 days ago
Brepco Biopharma and Piramal Critical Care have announced that Neoatricon®, a paediatric formulation for treating hypotension in neonates, infants, and children, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
positive
Piramal Critical Care's Neoatricon® Receives MHRA Approval in UK5 days ago
Brepco Biopharma and Piramal Critical Care have announced that their paediatric formulation Neoatricon® has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Neoatricon® is designed for the treatment of hypotension in neonates, infants, and children.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,764.75 4,28,233.30 35.92 49,887.20 12.06 9,648 13.77 61.58
5,840.65 1,56,910.50 74.97 8,184.00 0.89 1,600 64.53 55.23
1,511.20 1,23,084.40 24.45 26,520.70 14.17 4,155 47.38 60.28
3,245.05 1,10,720.70 58.75 10,785.70 11.59 1,656 13.54 61.68
1,177.90 1,00,988.70 18.34 28,905.40 12.36 5,578 1.69 51.86
2,398.05 97,867.10 48.47 10,615.60 19.57 1,942 -16.38 56.07
2,068.75 96,711.60 32.93 20,141.50 19.94 1,936 38.82 54.50
907.35 92,945.80 20.14 19,831.50 13.82 3,831 29.92 48.54
1,194.95 70,253.80 19.68 29,559.20 17.55 3,169 -10.04 61.05
31,101.85 66,026.50 49.49 6,097.20 10.80 1,201 16.01 61.04
Growth Rate
Revenue Growth
14.23 %
Net Income Growth
-109.54 %
Cash Flow Change
107.60 %
ROE
-108.36 %
ROCE
173.33 %
EBITDA Margin (Avg.)
40.67 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,345
1,612
1,709
2,229
1,574
1,777
1,814
2,196
1,802
1,980
2,034
2,591
1,993
2,320
2,233
Expenses
1,197
1,381
1,314
1,733
1,465
1,554
1,629
1,812
1,617
1,646
1,723
2,053
1,747
1,900
1,867
EBITDA
148
231
395
495
109
223
185
384
185
334
312
538
246
420
367
Operating Profit %
9 %
12 %
15 %
19 %
1 %
10 %
5 %
16 %
8 %
14 %
12 %
20 %
10 %
15 %
15 %
Depreciation
136
138
147
165
162
166
164
184
174
185
186
196
185
192
197
Interest
42
49
50
57
62
83
95
104
119
110
106
114
107
108
103
Profit Before Tax
-30
44
198
273
-115
-26
-74
95
-107
40
19
228
-45
120
67
Tax
-2
7
35
69
-6
11
17
45
-9
35
9
126
44
98
63
Net Profit
-28
37
163
204
-109
-37
-90
50
-99
5
10
101
-89
23
4
EPS in ₹
0.00
0.31
1.38
1.72
-0.92
-0.31
-0.76
0.42
-0.83
0.04
0.08
0.77
-0.67
0.17
0.03

Balance Sheet

Balance Sheet
2021
2022
2023
2024
Total Assets
10,900
12,797
14,523
15,312
Fixed Assets
6,106
6,879
7,469
7,990
Current Assets
3,649
4,067
4,836
5,465
Capital Work in Progress
627
1,172
1,419
1,116
Investments
123
267
639
385
Other Assets
4,045
4,478
4,996
5,821
Total Liabilities
10,900
12,797
14,523
15,312
Current Liabilities
2,490
3,033
3,843
4,369
Non Current Liabilities
2,805
3,067
3,906
3,031
Total Equity
5,605
6,697
6,774
7,911
Reserve & Surplus
4,610
5,511
5,580
6,588
Share Capital
995
1,186
1,193
1,323

Cash Flow

Cash Flow
2021
2022
2023
2024
Net Cash Flow
110
-177
-32
166
Investing Activities
-4,464
-1,737
-1,334
-416
Operating Activities
598
766
484
1,005
Financing Activities
3,977
794
818
-422

Share Holding

% Holding
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
34.79 %
0.00 %
34.79 %
34.79 %
34.79 %
35.02 %
35.02 %
35.02 %
35.02 %
34.95 %
34.95 %
34.95 %
FIIs
20.00 %
0.00 %
20.00 %
20.00 %
20.00 %
18.04 %
32.37 %
32.51 %
30.59 %
31.42 %
31.73 %
31.68 %
DIIs
4.86 %
0.00 %
5.28 %
4.99 %
5.49 %
7.83 %
8.02 %
9.68 %
12.12 %
12.95 %
13.81 %
14.10 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.42 %
0.00 %
11.80 %
13.94 %
16.77 %
16.81 %
16.95 %
15.57 %
15.13 %
13.94 %
13.29 %
13.29 %
Others
32.92 %
100.00 %
28.14 %
26.29 %
22.95 %
22.30 %
7.64 %
7.22 %
7.14 %
6.74 %
6.22 %
5.98 %
No of Share Holders
1,79,957
1,79,948
2,29,960
2,41,359
2,77,270
2,95,773
2,97,225
2,92,312
2,97,996
3,06,398
3,59,751
4,18,442

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.11 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.84 0.00 0.05 0.00

Corporate Action

Announcements

Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
4 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release
5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Mar 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper Publication
Feb 20, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Feb 19, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -US FDA Inspection At Piramal PharmaS Facility Located At Turbh
Feb 18, 2025
Intimation For Change In Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer Agent (RTA) Of Company
Feb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 17, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Extension Of Timeline Communicated For Sale Of CompanyS Unit Situated At Thane
Jan 31, 2025
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Jan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 29, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Issuance Of Corp
Jan 29, 2025
Integrated Filing (Financial)
Jan 28, 2025
Announcement under Regulation 30 (LODR)-Investor Presentation
Jan 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 28, 2025
Announcement under Regulation 30 (LODR)-Change in Directorate
Jan 28, 2025
Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended 31St December 2024
Jan 28, 2025
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited (Company) Held On 28Th January 2025
Jan 28, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations)
Jan 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 22, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Issuance Of Corp
Jan 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 13, 2025
Board Meeting Intimation for Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)
Jan 13, 2025
Announcement under Regulation 30 (LODR)-Change in Management
Jan 06, 2025
Intimation For Change In The Name Of The Registrar And Share Transfer Agent Of The Company
Jan 02, 2025
Intimation Regarding Change Of Name Of Registrar And Transfer Agent (RTA) Of The Company From Link Intime India Private Limited To MUFG Intime India Private Limited
Jan 02, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')- Update On Litigation
Dec 06, 2024
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ('SEBI Listing Regulations')-Issuance Of Corporate Guarantee
Nov 08, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Oct 29, 2024
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Oct 26, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Oct 24, 2024
Announcement under Regulation 30 (LODR)-Investor Presentation
Oct 23, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Oct 23, 2024
Unaudited Financial Results For Quarter And Half Year Ended 30Th September 2024
Oct 23, 2024
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited ('Company') Held On 23Rd October, 2024
Oct 23, 2024
Announcement under Regulation 30 (LODR)-Credit Rating
Oct 22, 2024
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ('SEBI Listing Regulations')
Oct 21, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Oct 14, 2024
Board Meeting Intimation for Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (''Listing Regulations'')
Oct 14, 2024
Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ('SEBI Listing Regulations')
Oct 10, 2024
Announcement under Regulation 30 (LODR)-Change in Management
Oct 08, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Oct 03, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Oct 03, 2024
Sustainability Report Of Piramal Pharma Limited ('The Company') For The Financial Year 2023-24
Oct 03, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sep 30, 2024
Announcement under Regulation 30 (LODR)-Meeting Updates
Sep 30, 2024
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- Receipt Of Establishment Inspection Report ('EIR') With Respect To US FDA Inspection At Piramal Pharma'S Manufacturing Facility Located At Ahmedabad, India
Sep 28, 2024
Announcement under Regulation 30 (LODR)-Investor Presentation
Sep 24, 2024

Technical Indicators

RSI(14)
Neutral
61.01
ATR(14)
Volatile
11.05
STOCH(9,6)
Overbought
84.60
STOCH RSI(14)
Overbought
85.72
MACD(12,26)
Bullish
3.89
ADX(14)
Weak Trend
18.68
UO(9)
Bearish
50.11
ROC(12)
Uptrend And Accelerating
13.16
WillR(14)
Neutral
-24.56

About Piramal Pharma

Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics (CHG) business, and an India Consumer Healthcare (ICH) business. Piramal Pharma Solutions provides integrated drug discovery, development, and manufacturing services. The company has a joint venture with Allergan in ophthalmology and a minority investment in Yapan Bio for biologics and vaccines. It is a leading player in India's self-care space with established brands. The company specializes in niche areas such as highly potent APIs, antibody drug conjugates, and biologics. In 2022, Piramal Pharma Limited was listed on the BSE and NSE following a demerger from Piramal Enterprises Limited.
Chairperson NameNandini Piramal